Geometric mean Titer of SARS-CoV-2 specific neutralizing antibody (wild Strains) on the 15th day after the full course of vaccination;Geometric mean Titer of SARS-CoV-2 specific neutralizing antibody(wild Strains) on the 15th day after the full course of vaccination;the incidence and severity of adverse events leading to withdrawal within 30 days after each dose of vaccination;the incidence and severity of adverse events leading to withdrawal within 30 days after each dose of vaccination;the incidence and severity of adverse events leading to withdrawal within 40 days after each dose of vaccination;the incidence and severity of adverse events leading to withdrawal within 60 days after each dose of vaccination;the incidence and severity of adverse reactions/events within 0-7 days after each dose of vaccination;the incidence and severity of adverse reactions/events within 0-7 days after each dose of vaccination;the incidence and severity of any adverse reactions/events within 30 minutes after each dose of vaccination;the incidence and severity of any adverse reactions/events within 30 minutes after each dose of vaccination;the incidence and severity of non-collective adverse reactions/events within 30 days after each dose of vaccination;the incidence and severity of non-collective adverse reactions/events within 30 days after each dose of vaccination;the incidence and severity of non-collective adverse reactions/events within 40 days after each dose of vaccination;the incidence and severity of non-collective adverse reactions/events within 60 days after each dose of vaccination;the incidence of abnormal blood biochemistry, blood routine, blood coagulation function and urine routine on the 4th day after each dose of vaccination;the incidence of AESI from the first dose of vaccination to 12 months after the full course of vaccination;the incidence of AESI from the the first dose of vaccination to 12 months after the full course of vaccination;the incidence of SAE from the first dose of vaccination to 12 months after the full course of vaccination;the incidence of SAE from the first dose of vaccination to 12 months after the full course of vaccination

Geometric mean Titer of SARS-CoV-2 specific neutralizing antibody (wild Strains) on the 15th day after the full course of vaccination;Geometric mean Titer of SARS-CoV-2 specific neutralizing antibody(wild Strains) on the 15th day after the full course of vaccination;the incidence and severity of adverse events leading to withdrawal within 30 days after each dose of vaccination;the incidence and severity of adverse events leading to withdrawal within 30 days after each dose of vaccination;the incidence and severity of adverse events leading to withdrawal within 40 days after each dose of vaccination;the incidence and severity of adverse events leading to withdrawal within 60 days after each dose of vaccination;the incidence and severity of adverse reactions/events within 0-7 days after each dose of vaccination;the incidence and severity of adverse reactions/events within 0-7 days after each dose of vaccination;the incidence and severity of any adverse reactions/events within 30 minutes after each dose of vaccination;the incidence and severity of any adverse reactions/events within 30 minutes after each dose of vaccination;the incidence and severity of non-collective adverse reactions/events within 30 days after each dose of vaccination;the incidence and severity of non-collective adverse reactions/events within 30 days after each dose of vaccination;the incidence and severity of non-collective adverse reactions/events within 40 days after each dose of vaccination;the incidence and severity of non-collective adverse reactions/events within 60 days after each dose of vaccination;the incidence of abnormal blood biochemistry, blood routine, blood coagulation function and urine routine on the 4th day after each dose of vaccination;the incidence of AESI from the first dose of vaccination to 12 months after the full course of vaccination;the incidence of AESI from the the first dose of vaccination to 12 months after the full course of vaccination;the incidence of SAE from the first dose of vaccination to 12 months after the full course of vaccination;the incidence of SAE from the first dose of vaccination to 12 months after the full course of vaccination